top of page
LATEST NEWS
enGene's Non-Viral Gene Therapy for Bladder Cancer Heads to the FDA
enGene's non-viral gene therapy detalimogene cleared detectable cancer in 56% of evaluated patients with BCG-unresponsive bladder cancer, and 86% kept their bladders. The company plans to start its FDA application by the end of 2026.
5 days ago3 min read


One CRISPR Infusion Cut Triglycerides 63% in People With Severe Hypertriglyceridemia
At AHA 2026, CRISPR Therapeutics reported that one fixed dose of CTX310 lowered ANGPTL3 by 65% and triglycerides by 63% in 10 people with severe hypertriglyceridemia, with no treatment-related serious side effects.
Nov 104 min read


Beam's Base-Edited Sickle Cell Therapy Hits Its Pivotal Goal, Setting Up the First Base-Editing BLA
Beam Therapeutics says risto-cel met its pivotal endpoint of at least 12 months free of severe pain crises in the BEACON trial, and plans to seek FDA approval as early as the end of 2026.
Nov 104 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


FDA Approves BEQVEZ: A Breakthrough One-Time Gene Therapy for Adults with Hemophilia B
Gene therapy is transforming the landscape of treatment options, and the recent FDA approval of BEQVEZ marks a significant milestone for individuals living with hemophilia B. This innovative one-time gene therapy replaces the need for regular infusions of clotting factor, offering new hope for patients suffering from this genetic disorder. Understanding Hemophilia B Hemophilia B is a genetic condition caused by mutations in the human factor IX gene, leading to a deficiency i
May 1, 2024
bottom of page


